This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Sarepta, Inovio, FDA Calendar, Ken Luskin's Angry Vical Voice Mail

Luskin, last seen holding millions of shares of Eastman Kodak as it plunged into bankruptcy, is now betting big on Vical. On allovectin-7 in a recent Seeking Alpha article, Luskin says, "I expect that Allovectin-7 will become one of the best selling cancer drugs of all time."

I disagree with Luskin on allovectin-7. I don't believe the drug will be successful in this ongoing phase III skin cancer study. [Results expected later this month.] Disagreeing with Luskin makes him mad. Very mad. When Luskin finds out that you disagree with him about a stock, he will call and email you to argue his point of view. [He will also post thousands of times -- literally -- on Internet stock message boards.] When he fails to convince you that he's right, he will call and email you more, often several times a day. His calls and emails will become more argumentative and hostile. If you ask Luskin nicely to refrain from calling and emailing you, he will yell, accusing you of conspiring with short sellers to manipulate lower the price of his beloved stock.

If you finally lose patience with Luskin and call him a whackadoodle, he will leave you a voice mail just like this one he left me on July 30 at 6:15 pm ET. (Saved on my iPhone.)

Luskin to me:

Hey you little piece of shit. You call me fucking names in public? I'll fucking destroy you. I'll fucking destroy you, you understand you little piece of shit? You be fucking nice! You're too much of a little fucking piece of shit, alright? You fuckhead! You understand? YOU FUCK WITH ME I'LL FUCK YOU UP!

Sorry about the avalanche of F bombs, but all of Luskin's subtleties would be lost without them.

You want more hate mail? Okay, "Johhny" isn't happy with my bearish call on GTX (GTXI) and its cancer muscle wasting drug enobasarm:

You will sharing a cell with Steven Cohen. Between your "twitter survey" and your friend who shorts biotech companies, you are doing your personal best to destroy GTX. The SEC will bring you down to your knees as a self promoter of your "short" friends. No matter what you continue to write, the FDA will have the final decision and you will get what you deserve in the end. I hope you get cancer and die from the chemo.

The dying from chemo thing was a nice touch.

As far as I can tell, nothing has changed at Inovio Pharmaceuticals (INO - Get Report). The company is still flogging the synthetic vaccine and electroporation vaccine delivery technologies of 30 years ago. The other constant is Inovio's relentless self promotion. Two big changes over this time period: 1) Inovio's pipeline products fail or disappear, and 2) one group of disgruntled and money-losing retail investors is replaced by a new crowd of doe-eyed investors believing Inovio has turned the corner. Of course, this is never true. Rinse. Repeat.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RNA $18.65 0.00%
GALE $0.76 0.00%
INO $6.19 0.00%
SRPT $11.73 0.00%
VICL $0.32 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs